Description
Retatrutide is a 39-amino acid peptide engineered based on the GIP peptide backbone, functioning as a novel triple-agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Through its triple-agonist action, Retatrutide may demonstrate groundbreaking therapeutic efficacy.